MacroGenics’ Margetuximab advantages could be ‘compelling’: H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating and $39 price target on MacroGenics after the American Association for Cancer Research, or AACR, conference. The analyst said, “Importantly, the underlying advantages [of Margetuximab] over trastuzumab could translate into compelling OS trends favoring margetuximab, in our view,” with data expected during Q1 of 2020.
https://thefly.com/landingPageNews.php?id=2888827